Stockscreener 앱 받기
6.205
12.31%
-0.865
시간 외 거래:
6.14
-0.065
-1.05%
전일 마감가:
$7.07
열려 있는:
$7.17
하루 거래량:
2.05M
Relative Volume:
2.54
시가총액:
$326.98M
수익:
-
순이익/손실:
$-14.14M
주가수익비율:
-6.7446
EPS:
-0.92
순현금흐름:
$-12.64M
1주 성능:
+0.81%
1개월 성능:
+47.27%
6개월 성능:
+163.83%
1년 성능:
+203.92%
1일 변동 폭
$6.05
$7.17
1주일 범위
$6.05
$7.73
52주 변동 폭
$1.34
$7.73
Immix Biopharma Inc Stock (IMMX) Company Profile
명칭
Immix Biopharma Inc
전화
(888) 958-1084
주소
11400 WEST OLYMPIC BLVD., LOS ANGELES
IMMX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
6.205 | 372.56M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immix Biopharma Inc 주식(IMMX)의 최신 뉴스
Immix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street Zen - Defense World
Immix Biopharma Inc Stock Analysis and ForecastGeopolitical Risk Analysis & Minimal Risk High Reward - earlytimes.in
Trendlines Converge — Decision Point for Tirupati Starch and Chemicals LimitedTake Profit Strategies & Compound Your Gains With Quality Stocks - earlytimes.in
Immix Biopharma FY2025 EPS Forecast Boosted by HC Wainwright - Defense World
Aug Summary: Will Immix Biopharma Inc stock benefit from infrastructure spending2025 Macro Impact & Verified Entry Point Detection - moha.gov.vn
FY2025 EPS Estimates for Immix Biopharma Lifted by Analyst - MarketBeat
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition (IMMX) - Seeking Alpha
Immix Biopharma Stock Surges 70%, With A 6-Day Winning Spree - Trefis
Immix Biopharma CFO Gabriel Morris buys $5k in shares By Investing.com - Investing.com Canada
Ilya Rachman, Immix Biopharma CEO, buys $4975 in shares By Investing.com - Investing.com Canada
Immix Biopharma CFO Gabriel Morris buys $5k in shares - Investing.com
Ilya Rachman, Immix Biopharma CEO, buys $4975 in shares - Investing.com
Immix Biopharma stock price target raised to $12 from $8 at H.C. Wainwright - Investing.com Australia
Immix Biopharma stock price target raised to $12 from $8 at H.C. Wainwright By Investing.com - Investing.com South Africa
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Sahm
IMMX Analyst Rating Update: HC Wainwright Raises Price Target to - GuruFocus
Immix Biopharma closes $93.7 million public offering By Investing.com - Investing.com Canada
Immix Biopharma closes $93.7 million public offering - Investing.com
Immix Biopharma announces closing of upsized $100 million underwritten offering of common stock and pre-funded warrants - marketscreener.com
Immix Biopharma, Inc. Closes $93.7 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Immix Biopharma prices $100M equity raise via common stock and warrant offering - MSN
Taking the lead: Immix Biopharma Inc (IMMX) - setenews.com
Immix Biopharma — Promising NEXICART-2 data; runway extended - Smartkarma
Immix Biopharma Enters Underwriting Agreement with Morgan Stanley - TipRanks
Form 424B5 Immix Biopharma, Inc. - StreetInsider
Immix Biopharma’s Market Dynamics Amid Economic Shifts - timothysykes.com
Immix Soars On NXC-201 Data In Relapsed/Refractory AL Amyloidosis; BLA Planned For 2026 - Nasdaq
Immix Biopharma Prices $100 Million Offering - marketscreener.com
Immix Biopharma Announces Positive Phase 2 Trial Results - TipRanks
Form FWP Immix Biopharma, Inc. Filed by: Immix Biopharma, Inc. - StreetInsider
Immix Biopharma, Inc. Announces Positive Phase 2 NXC-201 Results - TradingView — Track All Markets
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Sahm
Immix Biopharma prices $100 million public offering to fund AL amyloidosis drug - Investing.com Nigeria
Immix Biopharma reports 75% complete response rate for NXC-201 By Investing.com - Investing.com Nigeria
Immix Biopharma reports 75% complete response rate for NXC-201 - Investing.com India
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - Investing News Network
Immix Biopharma prices offering of 19.1 million shares at $5.10 per share - marketscreener.com
Immix Biopharma Prices Offering Of 19.1 Million Shares At $5.10 Per Share - TradingView — Track All Markets
Immix Biopharma (IMMX) sets price for upsized $100M stock and pre-funded warrant offering - Stock Titan
Immix Biopharma (IMMX) reports 75% CR at ASH 2025, plans 2026 NXC-201 BLA - Stock Titan
Best Biotech Stocks Right Now • Updated Daily - Benzinga
Is Immix Biopharma Inc (IMMX) positioned for future growth? - Setenews
Immix Biopharma, Inc.'s (NASDAQ:IMMX) market cap rose US$18m last week; retail investors who hold 56% profited and so did insiders - simplywall.st
Immix Biopharma (NASDAQ:IMMX) Trading 4.5% Higher – What’s Next? - Defense World
What analysts say about Immix Biopharma Inc stockSector Rotation Strategies & Our Experts Decode Market Noise for You - earlytimes.in
Is Immix Biopharma Inc a good long term investmentMarket Depth Overview & Watch and Learn From Live Trades - earlytimes.in
Immix Biopharma Inc (IMMX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Immix Biopharma Inc 주식 (IMMX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Dec 10 '25 |
Buy |
6.58 |
770 |
5,067 |
291,429 |
| Rachman Ilya M | CEO and Chairman |
Sep 17 '25 |
Buy |
2.02 |
2,500 |
5,050 |
1,140,937 |
| Morris Gabriel S | CFO |
Sep 16 '25 |
Buy |
1.97 |
2,600 |
5,122 |
290,659 |
| Rachman Ilya M | CEO and Chairman |
Jun 18 '25 |
Buy |
2.29 |
2,178 |
4,999 |
1,138,437 |
| Morris Gabriel S | CFO |
Jun 18 '25 |
Buy |
2.28 |
2,225 |
5,071 |
288,059 |
| Hsu Jason | Director |
Dec 23 '24 |
Buy |
2.19 |
40,000 |
87,680 |
893,000 |
| Hsu Jason | Director |
Dec 20 '24 |
Buy |
2.17 |
7,700 |
16,678 |
853,000 |
0.36%
1.12%
자본화:
|
볼륨(24시간):